Regression of Atherosclerosis by Amlodipine via Anti-Inflammatory and Anti-Oxidative Stress Actions
暂无分享,去创建一个
R. Chen | J. Higaki | M. Mogi | M. Iwai | M. Horiuchi | A. Oshita | Ayumi Ide | Zhen Li | Toyofumi Yoshii | Shiori Fukunaga
[1] I. Tabas. Consequences and Therapeutic Implications of Macrophage Apoptosis in Atherosclerosis: The Importance of Lesion Stage and Phagocytic Efficiency , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[2] T. Godfraind,et al. Calcium Channel Blocker Inhibits Western-Type Diet-Evoked Atherosclerosis Development in ApoE-Deficient Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.
[3] R. Chen,et al. Deletion of Angiotensin II Type 2 Receptor Exaggerated Atherosclerosis in Apolipoprotein , 2005 .
[4] Takahiro Shimizu,et al. Calcium Channel Blockades Exhibit Anti-Inflammatory and Antioxidative Effects by Augmentation of Endothelial Nitric Oxide Synthase and the Inhibition of Angiotensin Converting Enzyme in the NG-Nitro-L-Arginine Methyl Ester-Induced Hypertensive Rat Aorta: Vasoprotective Effects beyond the Blood Press , 2005, Hypertension Research.
[5] Jian-Mei Li,et al. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice , 2005, Journal of hypertension.
[6] T. Ishimitsu,et al. Protective Effects of an Angiotensin II Receptor Blocker and a Long-Acting Calcium Channel Blocker against Cardiovascular Organ Injuries in Hypertensive Patients , 2005, Hypertension Research.
[7] P. Libby,et al. Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure The CAMELOT Study: A Randomized Controlled Trial , 2004 .
[8] M. Matsuzaki,et al. Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.
[9] C. Zancanaro,et al. Involvement of the nitric oxide system in the anti-atherosclerotic potential of lacidipine in the ApoE-deficient mouse: a morphological, functional, and electrochemical study. , 2004, Toxicologic pathology.
[10] S. Takai,et al. Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.
[11] G. Mancia,et al. Absolute and relative changes in carotid intima–media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA) , 2004, Journal of hypertension.
[12] D. Ausiello,et al. Differential expression and targeting of endogenous Arf1 and Arf6 small GTPases in kidney epithelial cells in situ. , 2004, American journal of physiology. Cell physiology.
[13] M. Cooper,et al. Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis , 2004, Circulation.
[14] A. Takeshita,et al. Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. , 2004, American journal of physiology. Heart and circulatory physiology.
[15] F. Turnbull. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.
[16] J. Staessen,et al. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003 , 2003, Journal of hypertension.
[17] Tomoya Yamashita,et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. , 2002, The Journal of clinical investigation.
[18] Ding-liang Zhu,et al. Dual mechanism of action of amlodipine in human vascular smooth muscle cells , 2002, Journal of hypertension.
[19] J. Wilcox,et al. Upregulation of Nox‐Based NAD(P)H Oxidases in Restenosis After Carotid Injury , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[20] S. Holland,et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. , 2001, The Journal of clinical investigation.
[21] Peter Libby,et al. Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.
[22] D. Sorescu,et al. Novel gp91phox Homologues in Vascular Smooth Muscle Cells: nox1 Mediates Angiotensin II-Induced Superoxide Formation and Redox-Sensitive Signaling Pathways , 2001, Circulation research.
[23] D. Weiss,et al. Angiotensin II–Induced Hypertension Accelerates the Development of Atherosclerosis in ApoE-Deficient Mice , 2001, Circulation.
[24] Michael E. Miller,et al. Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events , 2000, Circulation.
[25] D. Sorescu,et al. NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.
[26] W. R. Taylor,et al. Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-alpha-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[27] G. Gaviraghi,et al. Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. , 1999, Journal of hypertension.
[28] S. Dhein,et al. Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium channel-blocking agent. , 1999, Circulation.
[29] N. Kobayashi,et al. Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. , 1999, Journal of cardiovascular pharmacology.
[30] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[31] K. Irani,et al. Shear-induced tyrosine phosphorylation in endothelial cells requires Rac1-dependent production of ROS. , 1999, American journal of physiology. Cell physiology.
[32] E. Schiffrin,et al. Apoptosis in vasculature of spontaneously hypertensive rats: effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. , 1998, American journal of hypertension.
[33] R. Ross,et al. Atherosclerosis is an inflammatory disease. , 1998, American heart journal.
[34] T. Hintze,et al. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. , 1998, Circulation.
[35] T. Saldeen,et al. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. , 1997, Journal of the American College of Cardiology.
[36] T. Nosek,et al. Increased superoxide production during fatigue in the perfused rat diaphragm. , 1997, American journal of respiratory and critical care medicine.
[37] P. Erne,et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Qiao,et al. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. , 1994, The Journal of clinical investigation.
[39] M. Cathcart,et al. Dual Ca2+ requirement for optimal lipid peroxidation of low density lipoprotein by activated human monocytes. , 1993, The Journal of clinical investigation.
[40] N. Maeda,et al. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.
[41] J. Wouter Jukema,et al. Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. , 2003, Journal of molecular and cellular cardiology.